Preclinical study demonstrates potent parasite growth inhibition in Plasmodium falciparum-infected red blood cells, indicating a viable pathway for affordable antimalarial therapies.
A novel class of molecules targeting aspartic proteinases from P. falciparum is described. Synthesis of these easily available, achiral, and highly potent molecules was supported by structural information and eventually allowed the identification of compounds highly active against three vacuolar aspartic proteinases. In a red blood cell assay, the growth of P. falciparum (strain K1) could be effectively prevented.
No takes yet. Share an insight, caveat, or question.
Boss et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: